# Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease

> **NCT02487199** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 18 (actual)

## Conditions studied

- Hepatitis C Virus (HCV)

## Interventions

- **DRUG:** ombitasvir/paritaprevir/ritonavir and dasabuvir
- **DRUG:** ombitasvir/paritaprevir/ritonavir

## Key facts

- **NCT ID:** NCT02487199
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-30
- **Primary completion:** 2016-12-05
- **Final completion:** 2016-12-05
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02487199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02487199, "Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02487199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*